Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€96.50

€96.50

-0.920%
-0.9
-0.920%
€140.00

€140.00

 
13:42 / Tradegate WKN: A2PSR2 / Name: BioNTech / Stock / Mid Cap /
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Latest predictions
03.06.25
-5.43%
buy
03.06.25
-6.26%
buy
€108.00
28.04.25
6.74%
buy
12.04.25
13.04%
buy
31.03.25
20.06%
buy
08.03.25
-2.82%
buy
Best running prediction
€85.00
19.07.24
22.15%
buy
Your prediction

BioNTech SE ADR Stock

BioNTech SE ADR shows a slight decrease today, losing -€0.900 (-0.920%) compared to yesterday.
BioNTech SE ADR is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
With a target price of 140 € there is a positive potential of 45.08% for BioNTech SE ADR compared to the current price of 96.5 €.
Our community identified positive and negative aspects for BioNTech SE ADR stock for the coming years. 32 users see the criterium "Worthwhile Investment for the next years" as a plus for the BioNTech SE ADR stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of BioNTech SE ADR in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When evaluating the financials of BioNTech, a company well-known for its innovative approach in the biotechnology industry, a mixed perspective emerges. Recent years have seen substantial growth and the broadening of its operational landscape, particularly accentuated by the global health crisis precipitated by the COVID-19 pandemic. However, the financial statements reflect complexities, indicating both potential and significant challenges that investors should ponder carefully.

Strong Income Generation: For the year ending 2023, BioNTech reported a net income of €930.3 million, showcasing its capability to generate substantial profit despite a competitive market landscape. This ability to translate sales into profit is crucial for any business, and with ongoing demand for vaccine technologies, this income could provide a sustainable path forward.

Robust Balance Sheet: An impressive total asset figure of €23 billion as of December 31, 2023 highlights BioNTech's strong market position. Importantly, cash reserves stand at €11.66 billion, which not only underscores liquidity but also positions the company well for future investments or R&D expenditures.

Comments

Prediction Buy
Perf. (%) 3.38%
Target price 170.000
Change
Ends at 17.12.22

Target price set to 170.0
Show more

Buy BioNTech SE ADR
Show more

Buy BioNTech SE ADR
Show more

News

BioNTech Stock: Strategic CureVac Acquisition Fuels Cancer Push
BioNTech Stock: Strategic CureVac Acquisition Fuels Cancer Push

BioNTech has unveiled plans to acquire former rival CureVac in a stock-based transaction valuing the Tübingen-based company at approximately $1.25 billion (€1.08 billion). This strategic move

BioNTech Stock: Q1 Losses Deepen Amid Leadership Change
BioNTech Stock: Q1 Losses Deepen Amid Leadership Change

BioNTech slipped deeper into the red during the first quarter of 2025, reporting a net loss of €415.8 million, significantly worse than the €315.1 million loss recorded in the same period last year

BioNTech Stock: Legal Setback in Moderna Patent Dispute
BioNTech Stock: Legal Setback in Moderna Patent Dispute

BioNTech faces a significant legal defeat as the Düsseldorf Regional Court ruled in favor of Moderna in a patent infringement lawsuit related to COVID-19 vaccine development. The Mainz-based company